1Alberto Corsini.The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk[J].Cardiovascular Drugs and Therapy.2003(3)
2Er-jia Wang,Christopher N. Casciano,Robert P. Clement,William W. Johnson.HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein[J].Pharmaceutical Research.2001(6)
3T. Kantola,J. T. Backman,M. Niemi,K. T. Kivist?,P. J. Neuvonen.Effect of fluconazole on plasma fluvastatin and pravastatin concentrations[J].European Journal of Clinical Pharmacology.2000(3)
4Schneck DW,Birmingham BK,Zalikowski JA,et al.The effect of gemfibrozil on the pharmacokinetics of rosuvastatin[].Clinical Pharmacology and Therapeutics.2004
5Editorial.The statin wars: why AstraZeneca must retreat[].The Lancet.2003
6Thompson PD,Clarkson P,Karas RH.Statinassociated myopathy[].The Journal of The American Medical Association.2003
7Waters D.Statins and safety: applying the results of randomized trials to clinical practice[].The American Journal of Cardiology.2003
8Farmer JA,Torre-Amione G.Comparative tolerability of the HMG-CoA reductase inhibitors[].Drug Safety.2000
9Downs JR,Clearfield M,Tyroler HA,et al.For the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).Additional perspectives on tolerability of long-term treatment with Iovastatin[].The American Journal of Cardiology.2001
10Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial[].The Lancet.2002
10Sever PS,Dahl of B,Poulter NR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration,in the angi o-scandinavian carsdic outcomes trial-lipid-lowering arm (ASCOT-LLA):a multicentre randomized controlled trial[J].Lancet,2003,361:1149-2258.
